Hawkes, E., Sarkozy, C., Song, Y., Ozcan, M., Morschhauser, F., Herrera, A., Akyol, A., Rao, P., Micco, A. D., Petel, A., Perna, S., Andreadis, C. (2025). Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy. Blood. https://doi.org/10.1182/blood-2025-3615